BluGlass (ASX:BLG) locks in A$1.4m Uviquity Phase II, hints at supply deal

The real prize is a potential long-term GaN laser supply agreement as Uviquity commercialises its deep-UV chip roadmap

BluGlass (ASX:BLG) has moved its Uviquity relationship out of the lab and one step closer to commercial supply. The Sydney-based gallium nitride laser maker today announced a A$1.4 million (US$1 million) Phase II commitment under its existing Joint Development Agreement with the US photonics company. Payments start in the third quarter of 2026 and run over the following year.

The headline dollar number is small. For a company still working towards meaningful product revenue, what matters more is what Phase II actually covers. The scope now spans photonic integrated circuit development, wafer and chip processing, packaging work, and direct purchases of BluGlass’ visible GaN laser products.

In other words, this is no longer a pure research collaboration. It has widened into engineering, packaging and product supply. And buried in CEO Jim Haden’s statement is the line investors should really focus on, which is the potential for a long-term manufacturing supply agreement as Uviquity commercialises its chip roadmap.

For a story that has been about capability building for years, that pivot toward supply is the part worth watching.

Why the Uviquity relationship graduates from R&D to product

Uviquity is not a name most ASX investors will know. It builds chip-based deep-UV light sources on an aluminium nitride platform, aimed at two very different end markets. One is analytical instrumentation for semiconductor, pharma and environmental use. The other is far-UVC disinfection, the human-safe wavelength that kills pathogens without harming skin.

The technical proof point sitting behind Phase II is Uviquity’s recently announced 229 nanometre deep-UV laser, which it claims is a world first at chip scale. BluGlass’ visible GaN lasers are being integrated into that platform, which is why the packaging and laser integration work now sits inside the JDA.

The commercial read is that Uviquity has moved far enough along its own roadmap to start buying product, not just co-developing it. That is a meaningful graduation.

The A$1.4m number matters less than the supply-agreement optionality

A$1.4 million spread over a year is not going to reshape BluGlass’ P&L. The company’s Phase I close, and the willingness of both sides to expand the relationship, tells us the technology fit is real.

The bigger prize sits in the phrase ‘long-term manufacturing supply agreement’. If Uviquity’s deep-UV products land with paying customers, BluGlass becomes an embedded laser supplier inside every unit shipped. That is the design-in dynamic Haden referenced, and it is how small photonics suppliers turn a single successful partner into recurring revenue.

We think this is the right frame for the announcement. Phase II is the option premium. The supply agreement is the underlying.

What still needs to prove out before this becomes a real revenue story

Two things need to happen for the design-in thesis to work. Uviquity has to actually ship its 229nm laser to paying customers, which management says begins with sampling later this year. And those samples then need to convert into orders at volumes that justify a long-term supply contract.

The skeptical read is that BluGlass has been in capability-building mode for a long time, and the pipeline of announcements has often outpaced the revenue line. This Phase II deal does not change that pattern by itself.

What it does do is give investors a specific commercial milestone to track over the next 12 to 18 months, rather than another vague research update.

The Investors Takeaway for BluGlass

The number today is small. The shape of the deal is what has changed. BluGlass is now selling product into Uviquity, packaging jointly, and holding an implicit option on a long-term supply agreement if the deep-UV platform commercialises.

For a company whose share price has long traded on future potential rather than shipped revenue, this is the kind of announcement that starts to close that gap. Investors can find more of our previous coverage of BluGlass at stocksdownunder.

The next data point to watch is Uviquity’s customer sampling later this year. That is the domino that either validates the design-in thesis or leaves BluGlass with another interesting R&D partner and no supply contract.